While preclinical FXR activation trials deliver negative regulatory signals that mitigate immune dysfunction in various liver diseases driven by inflammation, the clinical implications of these mechanisms in FXR-related conditions remain uncertain [173]. The gene discussed is NR1H4; the disease is liver disorder.